PepMD reaffirms standards push after FDA advisory talks

PepMD says recent FDA advisory discussions underscored the need for stronger clinical standards, education and evidence-building in the fast-changing peptide field. The Chicago-based standards body pointed to its credentialing, pharmacy recognition and research authorization programs as it looks to support responsible clinical practice.

Why it matters: - PepMD is positioning non-commercial standards as a key layer of oversight alongside regulation in the evolving peptide space. - The organization says clearer credentialing, pharmacy quality checks and research documentation can improve safety, accountability and trust for clinicians and patients.

What happened: - Karthik Achari, founder of PepMD, gave public comment on July 23, 2026, during the FDA Pharmacy Compounding Advisory Committee’s Open Public Hearing at the agency’s White Oak campus. - Achari did not argue for or against any specific peptide or regulatory outcome. - The remarks focused on clinician evaluation, pharmacy quality verification and turning real-world clinical experience into structured evidence. - PepMD said the FDA discussions reinforced its mission to build professional infrastructure for this area of healthcare.

The details: - PepMD describes itself as a private standards body building credentialing and trust infrastructure for this area of healthcare. - The organization says its framework has three connected initiatives: clinician credentialing, pharmacy recognition and research site authorization. - Clinician credentialing is intended to promote competency, continuing education and responsible clinical decision-making. - Pharmacy recognition is designed to identify organizations that meet defined quality expectations and add transparency without replacing regulatory oversight. - Research site authorization is intended to encourage standardized documentation and evidence development. - PepMD says these programs are meant to create a comprehensive trust infrastructure for practitioners, researchers, pharmacies and patients. - The organization says fields mature through more than regulation alone and need professional standards, continuing education, verification systems and evidence generation. - PepMD’s guiding principle is “The Standard for Clinical Excellence.” - The company website listed in the release is more information.

Between the lines: - The release frames PepMD as an infrastructure player, not a product marketer. - The timing suggests the organization is using FDA-level debate to validate a broader message: innovation needs systems that support consistent practice and credible evidence. - Achari said the discussion reinforced the need for standards, education and accountability as the field grows.

What's next: - PepMD says it plans to keep working with healthcare professionals, researchers and organizations focused on education, accountability and evidence development. - The organization expects regulatory discussions to continue while it keeps building standards it says can support responsible clinical practice. - Achari said the mission will not change based on any single meeting.

The bottom line: - PepMD is doubling down on standards, verification and evidence-building as the peptide field faces continued regulatory scrutiny.